The authors noted that this agreed with AFPE treatment of MDA-MB-231 breast cancer cells, whereby it inhibited AKT activation and downregulated several oncoproteins, such as NF-kB, c-myc, and β-catenin [142]. The gene discussed is AKT1; the disease is breast carcinoma.